GLP 1 receptor agonist - Arecor/TRx Biosciences
Alternative Names: Oral GLP-1Latest Information Update: 27 Jun 2025
At a glance
- Originator Arecor
- Developer Arecor; TRx Biosciences
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus; Obesity
Most Recent Events
- 27 Jun 2025 Preclinical trials in Diabetes mellitus in United Kingdom (PO), prior to June 2025 (Arecor pipeline, June 2025)
- 27 Jun 2025 Preclinical trials in Obesity in United Kingdom (PO), prior to June 2025 (Arecor pipeline, June 2025)
- 12 Mar 2024 Arecor and TRx Biosciences enter into research collaboration to develop oral GLP-1 receptor agonist with enhanced bioavailability